Teresa Graham

Head of Roche Pharmaceuticals

Appears in 1 story

Last updated Sep 22, 2026

Stories

Roche's dual GLP-1/GIP drug posts strong phase 2 diabetes results

New Capabilities

As of September 2026: Overseeing enicepatide's phase 3 program

Roche's experimental once-weekly diabetes injectable cut blood sugar and body weight in a 48-week phase 2 trial announced September 22. Patients on the highest 24 mg dose saw HbA1c drop 2.65 percentage points and weight fall 15.5%.

Updated Sep 22